The termination of the ATM removes a source of future equity capital, removing a path to raise funds through this facility. However, the stock's 63% decline since Sept 4 suggests the market already priced in the risk of dilution and distress. The company may seek to file a further supplement to increase capacity if non-affiliate market value rises above $75 million. Monitor for any new financing announcements or a further S-3/A for Armistice warrant exercise.
Price Chart
Executive Summary
bioAffinity Technologies filed a 424B5 prospectus supplement reducing the available shares under its ATM agreement with WallachBeth Capital to zero, effectively terminating the ATM facility. The company had previously sold $1.8 million under the shelf's I.B.6 capacity and cited insufficient non-affiliate market value to continue. This eliminates a source of potential future dilution, but the stock has collapsed from $15.27 (Sept 4) to $5.64 (Oct 8), reflecting severe distress.
Key Facts
- Supplement No. 1 reduces the dollar amount of common shares that may be sold under the ATM agreement to zero
- No further sales permitted under the At-the-Market Issuance Sales Agreement with WallachBeth Capital
- Non-affiliate market value of outstanding common stock is approximately $17.7 million, based on 1,159,630 shares at $15.27
- Company sold $1.8 million of common stock under General Instruction I.B.6 in the prior 12-month period
- Stock price dropped from $15.27 (Sept 4 closing) to $5.64 (Oct 64), a 63% decline
- Cross-filing context: S-3/A filed Sept 3 registered 1,692,408 shares for resale by Armistice Capital (282% potential dilution from August 2026 private placement)
- Company has a going concern opinion from auditor and persistent net losses ($14.9M in 2025)
Financial Impact
ATM facility terminated; no new equity sales permitted under this agreement. Prior 12-month sales totaled $1.8 million. Non-affiliate float valued at $17.7 million.
Risk Factors
- Company has a going concern opinion from auditor and persistent net losses
- Stock price has declined 63% from Sept 4 to Oct 8
- Potential future dilution from Armistice Capital warrants from August 2026 private placement
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-046449 |
| Document: 0001493152-26-046449-index-headers.html | 0001493152-26-046449 |
| Document: 0001493152-26-046449-index.html | 0001493152-26-046449 |
| Document: 0001493152-26-046449.txt | 0001493152-26-046449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | DEF 14A | $2.83 | awaiting T+60 | — | $2.96 (+4.59%) |
Oct 15, 2026 12d ago | 8-K | $3.96 | awaiting T+60 | — | $2.96 (−25.25%) |
Oct 13, 2026 14d ago | 8-K | $3.63 | awaiting T+60 | — | $2.96 (−18.34%) |
Oct 9, 2026 18d ago | 8-K | $3.90 | awaiting T+60 | — | $2.96 (+24.10%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (+37.35%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 | awaiting T+60 | — | $2.96 (−37.35%) |
Oct 8, 2026 19d ago | 8-K | $5.64 | awaiting T+60 | — | $2.96 (−47.52%) |
Oct 6, 2026 21d ago | 8-K | $6.06 | awaiting T+60 | — | $2.96 (−51.16%) |
Sep 30, 2026 27d ago | 8-K | $6.56 | awaiting T+60 | — | $2.96 (−54.88%) |
Sep 22, 2026 5w ago | 8-K | $8.56 | awaiting T+60 | — | $2.96 (−65.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers